Gerhardt Attard, MD, PhD, on Prostate Cancer: Results From an After-Market Study on Enzalutamide

2017 ASCO Annual Meeting
Tweet this page

Gerhardt Attard, MD, PhD, of The Royal Marsden Hospital and The Institute of Cancer Research, discusses trial results on continued enzalutamide post prostate-specific antigen progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer. (Abstract 5004)

Advertisement

Advertisement



Advertisement